ClinicalTrials.gov
ClinicalTrials.gov Menu

Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types (AcSé)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03012620
Recruitment Status : Recruiting
First Posted : January 6, 2017
Last Update Posted : May 18, 2018
Sponsor:
Collaborators:
National Cancer Institute, France
Ligue contre le cancer, France
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
UNICANCER

Brief Summary:
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available, in order to identify subsets of patients that may benefit from treatment

Condition or disease Intervention/treatment Phase
Sarcoma Ovarian Neoplasm Central Nervous System Neoplasm Thyroid Neoplasm Carcinoma, Neuroendocrine Neoplasms, Germ Cell and Embryonal NK/T-cell Lymphoma Drug: Pembrolizumab Phase 2

Detailed Description:

The study plans to enrol up to 350 patients in total with between 20 and 50 patients assigned to each cohort according to indication, as follows:

  • Cohort 1: Rare sarcoma
  • Cohort 2: Rare ovarian cancer
  • Cohort 3: Primary central nervous system lymphomas
  • Cohort 4: Rare thyroid cancer
  • Cohort 5: Rare malignant neuroendocrine cancer
  • Cohort 6: Germ-cell cancer
  • Cohort 7: NK/T-cell lymphoma

The study will use a two-stage Bayesian enrichment design. The first stage treats all patients from the different cohorts with the investigational product and identifies possibly sensitive indications. The second stage will compare outcomes among subsets of patients in the identified cohorts to distinguish between subpopulations of patients who may benefit from the treatment and patients for whom there is no evidence of efficacy.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types
Actual Study Start Date : July 5, 2017
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Experimental: Pembrolizumab
Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
Drug: Pembrolizumab
Treatment
Other Names:
  • MK-3475
  • KEYTRUDA




Primary Outcome Measures :
  1. Objective response rate [ Time Frame: measured at the first scheduled disease assessment following study treatment initiation (Day 84, ± 7 days) ]
    ORR will be assessed per cohort by an IRC according to RECIST v1.1.


Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months ]
    Assessed according to RECIST v1.1

  2. Overall survival [ Time Frame: From date of inclusion until the date of death from any cause, assessed up to 36 months ]
  3. Best response [ Time Frame: From inclusion up to 36 months ]
    Assessed according to RECIST v1.1

  4. Response duration [ Time Frame: from first observation of objective response until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months ]
    Assessed according to RECIST v1.1

  5. Time to response [ Time Frame: from inclusion first observation of objective response, assessed up to 36 months ]
    Assessed according to RECIST v1.1

  6. Frequency and severity of adverse events [ Time Frame: from inclusion until 100 days after last dose of investigational product ]
    Assessed according to the NCI-CTCAE v4

  7. Objective response rate in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34) [ Time Frame: measured at the first scheduled disease assessment following study treatment initiation (Day 84, ± 7 days) ]
    ORR will be assessed per cohort by an IRC according to RECIST v1.1

  8. Progression-free survival in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34) [ Time Frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months ]
    Assessed according to RECIST v1.1

  9. Overall survival in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34) [ Time Frame: From date of inclusion until the date of death from any cause, assessed up to 36 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient information sheet and written informed consent form signed.
  2. Histologically confirmed diagnosis of a pathology corresponding to one of the following selected cancer types:

    • Rare sarcoma: Alveolar soft part sarcoma, Chordoma, Dedifferentiated chondrosarcoma, epithelioid sarcoma, sarcoma with loss of INI1, malignant rhabdoid tumours, myxoid liposarcoma, angiosarcoma of the scalp, radiation induced sarcomas.
    • Rare ovarian cancer: recurrent or relapsed; sex cord tumour, germ cell tumour (immature teratoma, non seminomatous germ cell & dysgerminoma), low-grade serous carcinoma, mucinous carcinoma, clear cell adenocarcinoma, small cell carcinoma, and carcinosarcoma - with histological confirmation following review by members of the Tumeurs Malignes Rares Gynécologiques (TMRG) network (French rare gynaecological tumour group)
    • Primary central nervous system lymphoma (PCNSL): refractory primary intraocular and CNS lymphoma.
    • Rare thyroid cancer: differentiated thyroid carcinoma (Papillary, follicular, Hurthle cell (oncocytic), poorly differentiated thyroid carcinoma), medullary thyroid carcinoma, anaplastic thyroid carcinoma.
    • Rare malignant neuroendocrine tumour: poorly differentiated tumours refractory after 2 lines of chemotherapy, well differentiated tumours refractory after 4 lines of treatment, carcinoid tumours after 2 lines of treatment.
    • Germ-cell cancer progressing after standard therapy.
    • Natural killer T-cell lymphoma: extranodal NK/T-cell lymphoma regardless of localization that is resistant or refractory to prior L-asparaginase therapy.
  3. Metastatic disease or unresectable locally advanced malignancy that is resistant or refractory to standard therapy or for which standard therapy does not exist or is not considered appropriate by the Investigator.
  4. Aged ≥ 18 years old.
  5. Measurable disease according to RECIST v1.1 guidelines for solid tumours (Eisenhauer, 2009); or IPCG response criteria (Abrey, 2005) for patients in the PCNSL cohort. For patients with germ-cell cancer measurable disease is defined as measurable according to RECIST v1.1 and / or abnormal levels of AFP, hCG and LDH. For patients with NK/T-cell lymphoma measurable disease is defined as focal uptake in at least one nodal or extra-nodal site with a Lugano 5-PS score of 4 or 5 (Cheson, 2014).
  6. Able to provide a Formalin-fixed/paraffin-embedded (FFPE) biopsy sample of a metastatic site or primitive tumour tissue.

    Note: Patients for whom suitable archived biopsy material is not available must be willing to undergo a biopsy of a tumour lesion prior to study entry, unless this is medically contraindicated (e.g. site inaccessible or patient safety concerns).

  7. Patients must have a mandatory treatment-free interval of at least 21 days following previous systemic anti-cancer treatments.
  8. Patients who have received previous systemic anticancer treatment and/or radiotherapy should have recovered from any treatment related toxicity, to a level of ≤ grade 1 (according to NCI-CTCAE criteria, v 4.0) with the exception of Grade 2 alopecia.
  9. Adequate hematologic function (absolute neutrophil count [ANC] ≥ 1.0 x109/L, platelets ≥ 100 x109/L, haemoglobin ≥ 9 g/L) measured within 14 days of treatment initiation.
  10. Adequate renal function (creatinine clearance ≥ 50 mL/min using the MDRD or CKI EPI method) measured within 14 days of treatment initiation.
  11. Adequate hepatic function (serum bilirubin ≤ 1.5 x the reference upper limit of normal (ULN) unless due to Gilbert's syndrome; ASAT and ALAT ≤ 2,5 xULN) measured within 14 days of treatment initiation. For patients with documented liver metastasis ASAT/ALAT ≤ 5x ULN is acceptable.
  12. Strictly normal blood levels of calcium and magnesium, measured within 14 days of treatment initiation.
  13. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 (Oken, 1982).
  14. Estimated life expectancy ≥ 90 days.
  15. Patients who are sexually active must agree to use a medically accepted method of contraception (e.g. implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner, for participating women; condoms for participating men) or practice complete abstinence, beginning 14 days before the first administration of the investigational product (IP), while on treatment and for at least 5 months after the last administration of IP for female patients, and 7 months after the last administration of IP for male patients.
  16. Women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to the first administration of IP. If urine test results are positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  17. Women who are breastfeeding should discontinue nursing prior to the first administration of IP and for at least 120 days after the last administration of IP.
  18. Patients must be affiliated to a Social Security System or equivalent.

Exclusion Criteria:

  1. Prior treatment with an anti-PD1 or anti-PD-L1 antibody
  2. Eligible, and willing, to participate in a clinical trial of an alternative anticancer therapy targeting their disease which is open to accrual in France.
  3. Concurrent steroid medication at a dose greater than prednisone 10 mg/day or equivalent. For patients with PCNSL or germ-cell cancer, concurrent steroid medication at a dose greater than prednisone 20 mg/day or equivalent.
  4. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  5. History of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
  6. History of severe hypersensitivity reaction to any monoclonal antibody therapy
  7. Radiotherapy (except for brain and extremities) within 21 days prior to the first administration of IP.
  8. Treatment with other investigational drugs or participation in another clinical trial within 21 days prior to the first administration of IP or concomitantly with the trial.
  9. Has known symptomatic central nervous system (CNS) metastases. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.
  10. Has known carcinomatous meningitis or a history of leptomeningeal disease, except for patients with primary CNS lymphoma.
  11. Serum creatinine > 1.5 xULN or glomerular filtration rate (GFR) < 50 ml/min.
  12. Other malignancies within the past 5 years other than basal cell skin cancer or in situ carcinoma of the cervix.
  13. Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy.
  14. Active or chronic hepatitis B, hepatitis C and/or human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies), or a known history of active Tuberculosis bacillus.
  15. Has received a live vaccine within 30 days of planned start of study treatment. Note: Seasonal influenza vaccines for injection are generally inactivated vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
  16. Active alcohol or drug abuse.
  17. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.
  18. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03012620


Contacts
Contact: Daniel Couch +33 (0)1 80 50 12 96 d-couch@unicancer.fr

Locations
France
Gustave Roussy Cancer Campus Recruiting
Villejuif, France
Contact: Christophe Massard         
Sponsors and Collaborators
UNICANCER
National Cancer Institute, France
Ligue contre le cancer, France
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Christophe Massard, MD Gustave Roussy Cancer Campus

Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT03012620     History of Changes
Other Study ID Numbers: UC0105/1612
2016-002260-14 ( EudraCT Number )
First Posted: January 6, 2017    Key Record Dates
Last Update Posted: May 18, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Neoplasms
Lymphoma, T-Cell
Ovarian Neoplasms
Nervous System Neoplasms
Thyroid Neoplasms
Central Nervous System Neoplasms
Neoplasms, Germ Cell and Embryonal
Carcinoma, Neuroendocrine
Lymphoma, Non-Hodgkin
Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Nervous System Diseases
Head and Neck Neoplasms
Thyroid Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Adenocarcinoma